Partnership to Develop Clinical LC Methods for Rapid TDM Analysis


A new collaboration between Shimadzu and leading German research facility, the University Medical Centre Göttingen (UMG) will focus on the development of new clinical laboratory methods using liquid chromatography - mass spectrometry (LC-MS) for therapeutic drug monitoring (TDM) analysis. Measuring the concentration of drugs currently in the blood is important for determining the required next dosages of medication eg in the form of antibiotics, antiepileptics and antidepressants; a swift turnaround of test results is therefore especially important for emergency patients who demand a special treatment, or who are in intensive care.


While conventionally methods for conducting TDM tests has been the use of immunoassays, more recently clinical laboratories have been turning to LC-MS systems for this purpose, which can provide advantages of greater accuracy and fl exibility.


However, despite this overall superiority, methods using LC-MS have previously been diffi cult to apply in emergency cases because of the complexity of sample preparation. For instance, the high fl exibility of the LC-MS system also means that each target group of drugs requires its own column, mobile phase and analysis conditions such


as temperature. This means that it can take time to switch methods to start a new sample analysis, making it diffi cult for a clinical laboratory to quickly return analysis results to the doctors who need them.


Further progression and testing of Shimadzu’s CLAM-2030, which has shown high potential in simplifying, streamlining and speeding up LC-MS testing, forms the core of the new collaboration between the company and leading experts at UMG, including Professr Andreas Fischer and Dr Frank Streit, who will work on the development of new methods for multiple target groups of drugs. The team will also optimise these new methods on CLAM-2030 for fast and easy switching.


The collaboration with UMG takes place under the auspices of Shimadzu’s ambitious European Innovation Centre (EUIC) program, aimed at bringing top-level expertise in science, technology and society together with advances in technology to create new and better solutions for tomorrow.


More information online: ilmt.co/PL/G2Rj 59152pr@reply-direct.com


Frank Streit


Company-wide Commitment to Science-based Emissions Reduction


Award Reflects Shining Example of International Collaboration


Since 1958 Dutch laboratory dealer Beun de Ronde BV, a provider of scientifi c equipment with a history going back 100 years, has been one of Lauda Dr R. Wobser GmbH & Co. KG’s most reliable partners, the two family companies having worked side-by-side together almost from the very beginning. After the death of the two company founders Beun and de Ronde, their long-standing, trusted colleague Joop Klinkenberg took over the shares and the company management, which he later passed down to his son Mike. To honour this extraordinary and close partnership, the current Managing Director Mike Klinkenberg has been awarded the Dr Rudolf Wobser Medal. At a celebratory dinner at the company headquarters near Amsterdam, the President & CEO of Lauda, Dr Gunther Wobser, presented the award in the presence of his father, Advisor and Shareholder, Dr Gerhard Wobser and the Managing Director of Beun de Ronde, Corné Reuvers.


Ursula Leuthold


In line with aims to limit global warming to 1.5°C and achieve net zero by 2050, Integra Biosciences is proud to announce that it has submitted company-wide emissions reduction targets through the Science Based Targets initiative (SBTi).


The SBTi partnership independently assesses and approves companies’ targets in line with strict criteria, helping to defi ne and support best practices for ambitious climate action in the private sector. To join this initiative, Integra has published a report summarizing the carbon footprint of its production sites and sales offi ces and publicly committed to the following emissions reduction targets:


A 42% reduction in absolute greenhouse gas emissions by 2031, and a 90% reduction by 2050.


To increase the annual percentage of renewable energy sources from 48% in 2021 to 100% by 2030.


A 51.6% reduction in greenhouse gas emissions along the value chain per revenue by 2031, and a 97% reduction by 2050.


Integra has outlined a comprehensive action plan to achieve this, and proactive developments are already in place to align with a net zero future while ensuring positive impacts for the company’s employees and the communities it serves.


Ursula Leuthold, Sustainability Coordinator at Integra Biosciences, commented: “Integra is proud to be setting 1.5°C-aligned science- based targets with SBTi, joining the global campaign to rapidly scale back greenhouse gas emissions. We believe that, by setting credible and independently validated emission targets, we can accelerate deep and urgent decarbonisation within our business and beyond.”


More information online: ilmt.co/PL/agPy 59203pr@reply-direct.com


Dr Gunther Wobser said: “The relationship between Lauda and Beun de Ronde is a very special one, because it was the fi rst agency that Lauda signed a contract with on 15th August, 1958. The collaboration goes back even further, as company founder Dr Rudolf Wobser knew Jan de Ronde from his previous work. Especially in the early days of our company, Beun de Ronde played a signifi cant role in our success, for which I would like to thank him on behalf of everyone involved. To this day, our partnership is the foundation of our shared economic success and can undoubtedly be regarded as a shining example of an international, neighborly collaboration between two family companies.”


The Dr Rudolf Wobser Medal, which is made of real gold, was created for the occasion of the 60th company anniversary in 2016 and is awarded to individuals who have made an extraordinary contribution to the


Pictured (left to right): Managing Directors of Beun de Ronde, Corné Reuvers and Mike Klinkenberg, with Dr Gerhard Wobser and President & CEO of Lauda, Dr Gunther Wobser


family company. For example, employees who have belonged to the company for over 50 years are honoured with the award. In total, 16 Dr Rudolf Wobser Medals have been awarded. Mike Klinkenberg was the fi rst person outside the company and outside Germany to receive this distinguished accolade.


More information online: ilmt.co/PL/5lMD 59183pr@reply-direct.com


Partnership to Advance Nanomaterials and Quantum Dot Technologies


Graphene and graphite producer Graphjet Technology Sdn Bhd has announced a new partnership with UK headquartered Quantum Science Ltd that will enhance both companies’ innovation pipelines.


Graphjet’s memorandum of agreement with Quantum Science will see the companies explore the technical and commercial opportunities of working together.


Plans are already underway for the two parties to create a fl agship new materials platform, with work due to start as soon as the agreement is fi nalised in early 2023. The companies will co-develop a range of new products that accelerate technological advances, with the aim of bringing new growth opportunities and improving the lives of hundreds of millions of people around the world.


Patrick Teh, Director UK and Europe at Graphjet, said that the collaboration with Quantum Science will “combine the strength and wisdom from both companies,” adding that “the perfect property synergy of graphene and QDs can make a revolution.”


The memorandum of agreement will see Quantum Science share


its expertise with Graphjet to advance both companies’ technology offerings to their customers.


Kuala Lumpur-based Graphjet transforms waste palm kernel shells into high-demand graphene materials for a range of technical industries.


Aiden Lee, CEO of Graphjet, said: “We are excited to team up with Quantum Science, a world leading QD innovator and developer, to advance our graphene products development and offerings. It will enable our ever-increasing customer base to access to the most advanced materials platform at unparalleled


cost advantages,


introducing new features and bringing signifi cant value to their businesses. We are pleased to continue our rapid forward progress as a sustainably sourced provider of graphite and graphene at a price that can be 80% less than competitors in a market using carbon- intensive production means resulting in lesser quality materials.”


More information online: ilmt.co/PL/XAnL and ilmt.co/PL/9RWy 59487pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80